Table 1.

Patient demographics and clinical characteristics.

Patient characteristic	Safety population			Total N = 31
	50 mg n = 3	100 mg n = 16	200 mg n = 12
Age, years
Mean (SD)	68.0 (6.6)	55.5 (15.1)	59.7 (10.9)	58.3 (13.2)
Sex, n (%)
Male	2 (67)	4 (25)	3 (25)	9 (29)
Female	1 (33)	12 (75)	9 (75)	22 (71)
Ethnicity
Not Hispanic or Latino	3 (100)	15 (94)	9 (75)	27 (87)
Hispanic or Latino	0	1 (6)	3 (25)	4 (13)
Race, n (%)a
White	3 (100)	14 (88)	10 (83)	27 (87)
Asian	0	2 (13)	1 (9)	3 (10)
Primary tumor type, n (%)
Colon/rectum	0	2 (13)	4 (33)	6 (19)
Pancreas	1 (33)	2 (13)	1 (8)	4 (13)
Ovary	1 (33)	0	1 (8)	2 (6)
Bladder	0	0	1 (8)	1 (3)
Breast	0	1 (6)	0	1 (3)
Cervix	0	1 (6)	0	1 (3)
Cholangiocarcinoma in gallbladder	0	1 (6)	0	1 (3)
Desmoplastic small round cell tumor	0	1 (6)	0	1 (3)
Epithelioid hemangioendothelioma	0	0 (0)	1 (8)	1 (3)
Gastric	0	1 (6)	0	1 (3)
Head and neck	0	1 (6)	0	1 (3)
Liver	1 (33)	0 (0)	0	1 (3)
Malignant neoplasm of parotid gland	0	1 (6)	0	1 (3)
Malignant perivascular epithelioid cell neoplasm	0	1 (6)	0	1 (3)
Melanoma	0	1 (6)	0	1 (3)
Mucoepidermoid cancer of parotid	0	0 (0)	1 (8)	1 (3)
Nasopharynx carcinoma	0	1 (6)	0 (0)	1 (3)
Non-small cell lung	0	0 (0)	1 (8)	1 (3)
Osteosarcoma	0	1 (6)	0	1 (3)
Pleomorphic adenoma	0	1 (6)	0 (0)	1 (3)
Prostate	0	0	1 (8)	1 (3)
Uterine perivascular epithelioid cell tumor	0	0	1 (8)	1 (3)
MTAP loss, n (%)	–	2 (13)	4 (33)	6 (19)
Time since diagnosis, days    Median (min, max)	735 (685, 1259)	596 (359, 3487)	923 (321, 2898)	765 (321, 3487)

Max maximum, min minimum, MTAP methylthioadenosine phosphorylase, SD standard deviation.

^aRace was not available for one patient in the 200-mg dose group.